Sanofi, SK Bioscience Launch Phase III Trial Program to Develop PCV21 for Pneumococcal Conjugate Vaccines

Posted on January 3, 2025 by admin

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers.